Kevin Joseph Fitzgerald sold $1.1M of ALNY
CSO & EVP, Head of Research at ALNYLAM PHARMACEUTICALS, INC.. 3,250 shares at an average of $323.62, traded Mar 2, 2026, filed Mar 4, 2026.
Score components
- +15RoleOfficer
- +25Trade size$1.1M at market
- +5Share of holdings soldSold 13% of holdings
- +15Cluster5 insiders selling within 14 days
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -2.6%, 3m -10.6%, 6m -18.3%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001735276-26-000051, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Mar 2, 2026 | AGrant or award Common Stock10b5-1 | +3,688 | $0.00 | $0 | 25,110 | Mar 4, 2026 |
| Mar 2, 2026 | SOpen-market sale Common Stock10b5-1 | -47 | $323.62 | $15k | 25,063 | Mar 4, 2026 |
| Mar 2, 2026 | SOpen-market sale Common Stock10b5-1 | -90 | $324.65 | $29k | 24,973 | Mar 4, 2026 |
| Mar 2, 2026 | SOpen-market sale Common Stock10b5-1 | -258 | $325.63 | $84k | 24,715 | Mar 4, 2026 |
| Mar 2, 2026 | SOpen-market sale Common Stock10b5-1 | -392 | $326.81 | $128k | 24,323 | Mar 4, 2026 |
| Mar 2, 2026 | SOpen-market sale Common Stock10b5-1 | -329 | $327.67 | $108k | 23,994 | Mar 4, 2026 |
| Mar 2, 2026 | SOpen-market sale Common Stock10b5-1 | -100 | $328.71 | $33k | 23,894 | Mar 4, 2026 |
| Mar 2, 2026 | SOpen-market sale Common Stock10b5-1 | -170 | $329.71 | $56k | 23,724 | Mar 4, 2026 |
| Mar 2, 2026 | SOpen-market sale Common Stock10b5-1 | -81 | $330.85 | $27k | 23,643 | Mar 4, 2026 |
| Mar 2, 2026 | SOpen-market sale Common Stock10b5-1 | -94 | $331.93 | $31k | 23,549 | Mar 4, 2026 |
| Mar 2, 2026 | SOpen-market sale Common Stock10b5-1 | -37 | $332.64 | $12k | 23,512 | Mar 4, 2026 |
| Mar 3, 2026 | SOpen-market sale Common Stock10b5-1 | -289 | $316.55 | $91k | 23,223 | Mar 4, 2026 |
| Mar 3, 2026 | SOpen-market sale Common Stock10b5-1 | -282 | $318.62 | $90k | 22,941 | Mar 4, 2026 |
| Mar 3, 2026 | SOpen-market sale Common Stock10b5-1 | -722 | $320.51 | $231k | 22,219 | Mar 4, 2026 |
| Mar 3, 2026 | SOpen-market sale Common Stock10b5-1 | -359 | $321.58 | $115k | 21,860 | Mar 4, 2026 |
| Mar 2, 2026 | AGrant or award Stock Option (right to buy)derivative10b5-1 | +8,105 | $0.00 | $0 | 8,105 | Mar 4, 2026 |
Related signals
Other insiders at ALNYLAM PHARMACEUTICALS, INC. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 36Weak | ALNYsell ALNYLAM PHARMACEUTICALS, INC. | Bryan Supran EVP, CLO and Secretary | $399k 1,758 shares | -12% | |
| 25Weak | ALNYLAM PHARMACEUTICALS, INC. | David E I Pyott director | $1.1M 3,830 shares | -71% | |
| 30Weak | ALNYLAM PHARMACEUTICALS, INC. | Melissa McLaughlin Chief Human Resources Officer | $1.3M 3,910 shares | -29% | |
| 26Weak | ALNYLAM PHARMACEUTICALS, INC. | Kevin Joseph Fitzgerald CSO & EVP, Head of Research | $418k 1,291 shares | -6% | |
| 51Moderate | ALNYLAM PHARMACEUTICALS, INC. | Tolga Tanguler EVP, Chief Commercial Officer | $746k 2,309 shares | -6% | |
| 59Moderate | ALNYLAM PHARMACEUTICALS, INC. | Jeffrey V. Poulton EVP, Chief Financial Officer | $797k 2,468 shares | -4% | |
| 64Notable | ALNYLAM PHARMACEUTICALS, INC. | Yvonne Greenstreet Chief Executive Officer | $948k 2,933 shares | -3% | |
| 40Moderate | ALNYLAM PHARMACEUTICALS, INC. | Pushkal Garg EVP Chief R&D | $1.5M 4,713 shares | -20% | |
| 65Notable | ALNYLAM PHARMACEUTICALS, INC. | Yvonne Greenstreet Chief Executive Officer | $2.2M 6,799 shares | -6% | |
| 48Moderate | ALNYLAM PHARMACEUTICALS, INC. | Tolga Tanguler EVP, Chief Commercial Officer | $524k 1,598 shares | -4% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.